Skip to main content

October 2014 - FRMC

Department

Conference Insider
11/03/2014
Chronic kidney disease is pervasive in the older population. The progression of CKD can have a significant affect on the overall prognosis of a geriatric patient.
Chronic kidney disease is pervasive in the older population. The progression of CKD can have a significant affect on the overall prognosis of a geriatric patient.
Chronic kidney disease is...
11/03/2014
First Report Managed Care
Conference Insider
11/03/2014
Anaheim­—In 2014, the Centers for Disease Control and Prevention (CDC) reported that >200 Americans die each day from a hospital-acquired infection. As such, healthcare professionals should be vigilant to reduce the risk of infection in...
Anaheim­—In 2014, the Centers for Disease Control and Prevention (CDC) reported that >200 Americans die each day from a hospital-acquired infection. As such, healthcare professionals should be vigilant to reduce the risk of infection in...
Anaheim­—In 2014, the Centers...
11/03/2014
First Report Managed Care
Conference Insider
11/03/2014
Anaheim­­—The goal of end-of-life care is to provide patients with the highest quality of care and the highest quality of life possible.
Anaheim­­—The goal of end-of-life care is to provide patients with the highest quality of care and the highest quality of life possible.
Anaheim­­—The goal of...
11/03/2014
First Report Managed Care
Conference Insider
11/03/2014
The Patient Protection and Affordable Care Act requires nursing homes to have an acceptable Quality Assurance and Performance Improvement plan.
The Patient Protection and Affordable Care Act requires nursing homes to have an acceptable Quality Assurance and Performance Improvement plan.
The Patient Protection and...
11/03/2014
First Report Managed Care
11/03/2014
Disorders that require antithrombotic and antiplatelet therapies are prevalent in long-term care (LTC).
Disorders that require antithrombotic and antiplatelet therapies are prevalent in long-term care (LTC).
Disorders that require...
11/03/2014
First Report Managed Care
11/03/2014
A forecasting model found that after 5 years, low-dose computed tomography lung cancer screening would result in 55,000 more lung cancer diagnoses, 11 million more scans, and $9.3 billion more in direct medical expenditures. 
A forecasting model found that after 5 years, low-dose computed tomography lung cancer screening would result in 55,000 more lung cancer diagnoses, 11 million more scans, and $9.3 billion more in direct medical expenditures. 
A forecasting model found that...
11/03/2014
First Report Managed Care
11/03/2014
Patients with radioiodine-resistant, advanced differentiated thyroid cancer who received lenvatinib had a significantly greater progression-free survival compared with patients who received placebo, according to new research.
Patients with radioiodine-resistant, advanced differentiated thyroid cancer who received lenvatinib had a significantly greater progression-free survival compared with patients who received placebo, according to new research.
Patients with...
11/03/2014
First Report Managed Care
11/03/2014
Chicago—At a median follow-up of 9.4 months, patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib had a significant increase in overall survival and progression-free...
Chicago—At a median follow-up of 9.4 months, patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib had a significant increase in overall survival and progression-free...
Chicago—At a median follow-up of...
11/03/2014
First Report Managed Care
11/03/2014
After a median follow-up of 5.7 years, an analysis found that premenopausal women with HR+ early breast cancer who received exemestane plus ovarian function suppression had a significant improvement in disease-free survival.
After a median follow-up of 5.7 years, an analysis found that premenopausal women with HR+ early breast cancer who received exemestane plus ovarian function suppression had a significant improvement in disease-free survival.
After a median follow-up of 5.7...
11/03/2014
First Report Managed Care
11/03/2014
Chicago—Patients with newly diagnosed mantle cell lymphoma (MCL) who received a bortezomib-based combination therapy had a significant increase in progression-free survival compared with a group who received standard frontline therapy.
Chicago—Patients with newly diagnosed mantle cell lymphoma (MCL) who received a bortezomib-based combination therapy had a significant increase in progression-free survival compared with a group who received standard frontline therapy.
Chicago—Patients with newly...
11/03/2014
First Report Managed Care